Peptide Derivative Nasal Delivery for Non-Invasive Eye Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Intravitreal injection for administering medicines to treat eye diseases is invasive and poses risks of infection and physical/mental strain, necessitating a less invasive administration method.

Innovation Solution

Development of a physiologically-active peptide derivative with a cell-penetration accelerating sequence and endosomal-escape accelerating sequence, optionally with a glycosylation molecule, for nasal administration to target the eye ball or optic nerve.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If intravitreal injection is used to administer medicine into the eye ball, then treatment effectiveness is improved, but patient comfort and safety deteriorate due to physical strain and infection risk

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidinfection risk and physical strain

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses a cell-penetration accelerating sequence (CPP) as an intermediary component attached to the peptide medicine. This CPP acts as a mediator that enables the peptide to penetrate ocular tissues and reach the target site (optic nerve or retina) through non-invasive nasal administration, eliminating the need for direct intravitreal injection while maintaining treatment effectiveness

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The peptide medicine is segmented into functional components: the physiologically-active peptide sequence and the cell-penetration accelerating sequence. This segmentation allows the CPP to perform the specific function of tissue penetration and delivery, while the peptide sequence provides the therapeutic effect, enabling separate optimization of each function

Inventive Principle:

Principle #1Segmentation

2Adaptability or versatility

If a peptide is used as medicine for eye diseases, then treatment options are expanded, but delivery to target site becomes more difficult due to peptide limitations

Engineering Contradiction:

Improvetreatment optionsVSAvoiddelivery to target site

Core Design Contradiction:

Adaptability or versatilityVSEase of operation

Solution Approach 1:

The patent creates a composite structure by attaching a cell-penetration accelerating sequence to the peptide molecule. This composite peptide derivative combines the therapeutic properties of the peptide with the penetration capabilities of the CPP, enabling effective delivery to ocular tissues through nasal administration

Inventive Principle:

Principle #40Composite materials

Solution Approach 2:

The patent modifies the physical and chemical parameters of the peptide by adding the CPP, which changes the peptide's ability to penetrate cell membranes and tissues. This parameter change enables the peptide to overcome its natural delivery limitations and reach the target site effectively

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enables non-invasive treatment of eye diseases by allowing the peptide derivative to migrate to the eye ball or optic nerve, providing a less invasive and effective therapeutic option.

Implementation Method 1

the functional sequence including a cell-penetration accelerating sequence

Methodology Applied

Scientific EffectCell penetration:

Implementation Method 2

the functional sequence including an endosomal-escape accelerating sequence

Methodology Applied

Scientific EffectEndosomal escape:

Implementation Method 3

further having a glycosylation molecule that includes a sugar chain

Methodology Applied

Scientific EffectGlycosylation:

Data Source

PatentUS20260049117A1Physiologically-active peptide derivative for treatment of eye diseases, pharmaceutical composition, nasal/nasal drop preparation, and use of physiologically-active peptide derivative

Publication Date: 2026.02.19 GLYTECH LLC

AI summary

A physiologically-active peptide derivative for treatment of an eye disease, the physiologically-active peptide derivative having a physiologically-active peptide sequence and a functional sequence, and the functional sequence including a cell-penetration accelerating sequence and an endosomal-escape accelerating sequence.